Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients

Non-small Cell Lung Cancer (NSCLC) Clinical Trial

Official title: Phase II Trial of Geriatric Evaluation as Selection Criteria and Predictive Factor of Safety in Elderly Patients (≥ 70 Years) With Non-small Cell Lung Cancer (NSCLC)That Can be Treated With Bevacizumab, Carboplatin and Paclitaxel

Status Active, not recruiting

Clinical Trial Summary

A phase II Study of an adapted chemotherapy regimen plus bevacizumab in elderly non-small cell lung cancer patients selected by geriatric assessment

Clinical Trial Description

CRITERIOS INCLUSION

• Written informed consent confirming that the patient understands the study objective and the procedures required.

• Patients must be able to accomplish with the study protocol.

• Men and women ≥70 years old.

• Histologically or cytologically confirmed diagnosis of non-squamous non-small cell lung cancer (NSCLC) with EGFR gen mutational status negative or non-determinable.

• Patients with stage IV disease.

• Patients who have not received first-line treatment

• Patients with ECOG performance status 0 or 1.

• Adequate bone marrow function, defined as:

• Absolute neutrophil count (ANC) ≥1.500/mm3 or ≥1.5x109/L;

• Hemoglobin ≥ 9 g/dL.

• Platelet count ≥ 100.000/mm3.

• Adequate renal function, defined as:

• Creatinine clearance ≥ 40 ml/min, according to MDRD formula.

• Urine dipstick proteinuria <2+. If urine dipstick for proteinuria ≥2+ 24 hours urine must be collected within 24 hours, and proteins must be less than 1 g.

• Fertile males must use an effective contraceptive method (error rate per year <1%) during the trial and until 6 months after the last study treatment dose, such as sexual abstinence, previous vasectomy and/or having a partner using any of following methods: implantables, injections, combined oral contraceptives and/or intrauterine device (hormonal only).

CRITERIOS EXCLUSION

• Previous chemotherapy for advanced NSCLC.

• History of haemoptysis grade ≥ 2 (defined as at least 2.5 mL of bright red blood) in the 3 months before inclusion.

• Major surgery (including open biopsy), significant traumatic injuries in the 28 days before inclusion or anticipation of the need of major surgical procedure during the treatment period

• Minor surgery, including permanent catheter insertion, in the 24 hours before bevacizumab infusion.

• Untreated brain metastases. Patients with CNS metastases treated with radiotherapy or surgery may be included if there is no evidence of progression after treatment

• Radiological evidence of a tumor that invades or is adjacent to a main blood vessel (e.g. lung artery or superior cava venous).

• Radiotherapy, in any lesion and for any reason, within 28 days before inclusion. Palliative radiotherapy for bone lesions within 14 days before inclusion is allowed.

• Treatment with aspirin (>325 mg/day) or clopidogrel (>75 mg/day) within 10 days prior to bevacizumab first dose. Use of full dose of oral or parenteral anticoagulants or thrombolytic agents in therapeutic doses. Prophylactic use of anticoagulant therapy is allowed.

• Uncontrolled hypertension (systolic BP >140 mmHg, diastolic BP >90mmHg) in the 28 days previous to inclusion or history of hypertensive crisis, or hypertensive encephalopathy.

• Clinically significant cardiovascular disease (i.e. cerebrovascular accident (CVA), myocardial infarction within 6 months prior to inclusion, unstable angina, congestive cardiac insufficiency NYHA ≥ II, left ventricular ejection fraction (LVEF) <50% or serious cardiac arrhytmia), not responding to treatment or that can interfere with trial treatment administration.

• Not healed wounds, active peptic ulcer or untreated bone fracture.

• Hypersensibility to any of the active ingredients of the study treatment (bevacizumab, carboplatine and paclitaxel) or any of its excipients.

• Serious cognitive impairment that limits the patient to understand and answer the study questionnaires.

• Inability to comply with the study protocol and/or follow-up procedures due to psychological, familiar, social or geographical problems

• Patients with an ADL score <5 at the screening.

• Patients with dementia: 9-12 points in the Folstein MMS at the screening.

• Patients accomplishing fragility Balducci criteria at the screening:

• Age ≥ 85 years old

• Dependence in 1 or more ADL

• >3 comorbilities

• >1 geriatric syndrome

OBJETIVOS

To assess the toxicity of the treatment in elderly patients (≥70 years) with NSC lung cancer who meet inclusion criteria for bevacizumab and selected based on a geriatric evaluation.

Determine predictive factors of toxicity in the elderly population (≥70 years). Determine objective response rate Determine disease control rate Determine progression free survival Determine overall survival Determine safety of the treatment combination

VARIABLES

Primary endpoint:

Rate of grade 3-4 neutropenia defined according to National Cancer Institute Common Terminology Criteria version 4.0 (NCI-CTC v4.0).

Secondary endpoints:

• Items of the Comprehensive Geriatric Assessment (CGA) scale as predictive factors for toxicity end-points.

• Objective response according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1).

• Progression-free survival.

• Overall survival. ;

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer (NSCLC)

• NCT number: NCT01980472
• Study type: Interventional
• Source: Grupo de Investigación y Divulgación Oncológica
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: August 2013
• Completion date: August 2017